2005
Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients
Menon S, Whitfield L, Sadis S, Meyer M, Leopold J, Lorusso P, Krishnamurthi S, Rinehart J, Nabell L, Croghan G. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. Journal Of Clinical Oncology 2005, 23: 3066-3066. DOI: 10.1200/jco.2005.23.16_suppl.3066.Peer-Reviewed Original Research
2004
Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients
Kraut E, Fishman M, Lorusso P, Steinberg J, Nieves J, Fetterly G, Darling I, Wanaski S, Dul J, Sherman J. Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients. Journal Of Clinical Oncology 2004, 22: 2501-2501. DOI: 10.1200/jco.2004.22.14_suppl.2501.Peer-Reviewed Original ResearchPharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients
Kraut E, Fishman M, Lorusso P, Steinberg J, Nieves J, Fetterly G, Darling I, Wanaski S, Dul J, Sherman J. Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients. Journal Of Clinical Oncology 2004, 22: 2501-2501. DOI: 10.1200/jco.2004.22.90140.2501.Peer-Reviewed Original Research